Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats

L. Vécsei, M. Flint Beal

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

In the present study the effects of kynurenine and its metabolite kynurenic acid were compared in different behavioral and pharmacological tests. Kynurenic acid administered i.c.v. resulted in ataxia and stereotypy in a dose-dependent manner (0.025-1.6 μmol). Administration of 0.8 μmol of kynurenic acid resulted in sleeping and an approximate 25% mortality of the animals. At a dose of 1.6 μmol all of the animals died within 2-5 min from cardiorespiratory failure. One hour after lower doses of kynurenic acid the behavior of the rats appeared normal (neither stereotypy nor ataxia were observed in their familiar environemnt), but their exploratory activity (0.025-0.2 μmol) was significantly lower in a novel environment (open-field box) compared to the control group. Twenty four hours after the injection of kynurenic acid the exploratory activity of the animals did not differ from the control group. Kynurenine administered i.c.v. in equimolar doses did not result in stereotypy, ataxia, sleeping or mortality of the animals although, immediately after high doses short-lasting (1-2 min) immobility was observed. The rearing activity of the high dose kynurenine-treated animals was lower 1 h after injection, but this effect disappeared 24 h after the treatment. Post-trial injection of kynurenic acid (0.2 μmol) slightly, but not significantly, inhibited the learning ability of the rats in an active avoidance paradigm. Kynurenine administered in an equimolar dose had no effect on the speed of learning, but significantly attenuated the intertriai activity of the rats. Kynurenic acid (0.2 μmol, 0.4 μmol) did not significantly inhibit the passive avoidance latency of the animals after post-trial treamtent. These findings suggest that i.c.v. administration of kynurenic acid results in marked acute behavioral changes while equimolar doses of kynurenine had only slight behavior effects. The present experiments and earlier behavioral data suggest that the NMDA receptor complex plays a role in specific cognitive functions.

Original languageEnglish
Pages (from-to)239-246
Number of pages8
JournalEuropean Journal of Pharmacology
Volume196
Issue number3
DOIs
Publication statusPublished - Apr 24 1991

Fingerprint

Kynurenic Acid
Kynurenine
Pharmacology
Ataxia
Injections
Learning
Control Groups
Aptitude
Mortality
N-Methyl-D-Aspartate Receptors
Cognition

Keywords

  • Ataxia
  • Kynurenic acid
  • Kynurenine
  • Learning
  • Memory
  • Open-field activity
  • Stereotypy

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats. / Vécsei, L.; Beal, M. Flint.

In: European Journal of Pharmacology, Vol. 196, No. 3, 24.04.1991, p. 239-246.

Research output: Contribution to journalArticle

@article{3e411971e5024b38af272138c5e2cc89,
title = "Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats",
abstract = "In the present study the effects of kynurenine and its metabolite kynurenic acid were compared in different behavioral and pharmacological tests. Kynurenic acid administered i.c.v. resulted in ataxia and stereotypy in a dose-dependent manner (0.025-1.6 μmol). Administration of 0.8 μmol of kynurenic acid resulted in sleeping and an approximate 25{\%} mortality of the animals. At a dose of 1.6 μmol all of the animals died within 2-5 min from cardiorespiratory failure. One hour after lower doses of kynurenic acid the behavior of the rats appeared normal (neither stereotypy nor ataxia were observed in their familiar environemnt), but their exploratory activity (0.025-0.2 μmol) was significantly lower in a novel environment (open-field box) compared to the control group. Twenty four hours after the injection of kynurenic acid the exploratory activity of the animals did not differ from the control group. Kynurenine administered i.c.v. in equimolar doses did not result in stereotypy, ataxia, sleeping or mortality of the animals although, immediately after high doses short-lasting (1-2 min) immobility was observed. The rearing activity of the high dose kynurenine-treated animals was lower 1 h after injection, but this effect disappeared 24 h after the treatment. Post-trial injection of kynurenic acid (0.2 μmol) slightly, but not significantly, inhibited the learning ability of the rats in an active avoidance paradigm. Kynurenine administered in an equimolar dose had no effect on the speed of learning, but significantly attenuated the intertriai activity of the rats. Kynurenic acid (0.2 μmol, 0.4 μmol) did not significantly inhibit the passive avoidance latency of the animals after post-trial treamtent. These findings suggest that i.c.v. administration of kynurenic acid results in marked acute behavioral changes while equimolar doses of kynurenine had only slight behavior effects. The present experiments and earlier behavioral data suggest that the NMDA receptor complex plays a role in specific cognitive functions.",
keywords = "Ataxia, Kynurenic acid, Kynurenine, Learning, Memory, Open-field activity, Stereotypy",
author = "L. V{\'e}csei and Beal, {M. Flint}",
year = "1991",
month = "4",
day = "24",
doi = "10.1016/0014-2999(91)90436-T",
language = "English",
volume = "196",
pages = "239--246",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats

AU - Vécsei, L.

AU - Beal, M. Flint

PY - 1991/4/24

Y1 - 1991/4/24

N2 - In the present study the effects of kynurenine and its metabolite kynurenic acid were compared in different behavioral and pharmacological tests. Kynurenic acid administered i.c.v. resulted in ataxia and stereotypy in a dose-dependent manner (0.025-1.6 μmol). Administration of 0.8 μmol of kynurenic acid resulted in sleeping and an approximate 25% mortality of the animals. At a dose of 1.6 μmol all of the animals died within 2-5 min from cardiorespiratory failure. One hour after lower doses of kynurenic acid the behavior of the rats appeared normal (neither stereotypy nor ataxia were observed in their familiar environemnt), but their exploratory activity (0.025-0.2 μmol) was significantly lower in a novel environment (open-field box) compared to the control group. Twenty four hours after the injection of kynurenic acid the exploratory activity of the animals did not differ from the control group. Kynurenine administered i.c.v. in equimolar doses did not result in stereotypy, ataxia, sleeping or mortality of the animals although, immediately after high doses short-lasting (1-2 min) immobility was observed. The rearing activity of the high dose kynurenine-treated animals was lower 1 h after injection, but this effect disappeared 24 h after the treatment. Post-trial injection of kynurenic acid (0.2 μmol) slightly, but not significantly, inhibited the learning ability of the rats in an active avoidance paradigm. Kynurenine administered in an equimolar dose had no effect on the speed of learning, but significantly attenuated the intertriai activity of the rats. Kynurenic acid (0.2 μmol, 0.4 μmol) did not significantly inhibit the passive avoidance latency of the animals after post-trial treamtent. These findings suggest that i.c.v. administration of kynurenic acid results in marked acute behavioral changes while equimolar doses of kynurenine had only slight behavior effects. The present experiments and earlier behavioral data suggest that the NMDA receptor complex plays a role in specific cognitive functions.

AB - In the present study the effects of kynurenine and its metabolite kynurenic acid were compared in different behavioral and pharmacological tests. Kynurenic acid administered i.c.v. resulted in ataxia and stereotypy in a dose-dependent manner (0.025-1.6 μmol). Administration of 0.8 μmol of kynurenic acid resulted in sleeping and an approximate 25% mortality of the animals. At a dose of 1.6 μmol all of the animals died within 2-5 min from cardiorespiratory failure. One hour after lower doses of kynurenic acid the behavior of the rats appeared normal (neither stereotypy nor ataxia were observed in their familiar environemnt), but their exploratory activity (0.025-0.2 μmol) was significantly lower in a novel environment (open-field box) compared to the control group. Twenty four hours after the injection of kynurenic acid the exploratory activity of the animals did not differ from the control group. Kynurenine administered i.c.v. in equimolar doses did not result in stereotypy, ataxia, sleeping or mortality of the animals although, immediately after high doses short-lasting (1-2 min) immobility was observed. The rearing activity of the high dose kynurenine-treated animals was lower 1 h after injection, but this effect disappeared 24 h after the treatment. Post-trial injection of kynurenic acid (0.2 μmol) slightly, but not significantly, inhibited the learning ability of the rats in an active avoidance paradigm. Kynurenine administered in an equimolar dose had no effect on the speed of learning, but significantly attenuated the intertriai activity of the rats. Kynurenic acid (0.2 μmol, 0.4 μmol) did not significantly inhibit the passive avoidance latency of the animals after post-trial treamtent. These findings suggest that i.c.v. administration of kynurenic acid results in marked acute behavioral changes while equimolar doses of kynurenine had only slight behavior effects. The present experiments and earlier behavioral data suggest that the NMDA receptor complex plays a role in specific cognitive functions.

KW - Ataxia

KW - Kynurenic acid

KW - Kynurenine

KW - Learning

KW - Memory

KW - Open-field activity

KW - Stereotypy

UR - http://www.scopus.com/inward/record.url?scp=0025777901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025777901&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(91)90436-T

DO - 10.1016/0014-2999(91)90436-T

M3 - Article

VL - 196

SP - 239

EP - 246

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 3

ER -